• How are payers responding to million-dollar price tags for advanced cell therapies?
• What performance metrics are being embedded in outcomes-based contracts for auto immune therapies?
• How do manufacturing complexities impact pricing strategies for personalized immunotherapies?
• What risk-sharing models are emerging between pharma companies and healthcare systems?
• How are real-world evidence platforms being used to validate long-term therapy value?
• What lessons can be drawn from oncology pricing models for immunology applications?
• How are patient advocacy groups influencing price transparency requirements?
• What impact will biosimilar competition have on first-gen biologic pricing structures?
• How are health technology assessment bodies updating evaluation frameworks for curative therapies?
• What innovative financing mechanisms are being tested in emerging markets?
• How does parallel trade affect price harmonization efforts in European markets?
• What role will AI play in predicting therapy adherence and pricing optimization?

• CAR-T Therapies
• Outcome-Based Contracts
• Health Economics
• Manufacturing Complexity
• Risk-Sharing Models
• Real-World Evidence
• Biosimilar Competition
• HTA Frameworks
• Patient Advocacy
• Parallel Trade
• Adherence Prediction
• Curative Therapy

• Request a Customized Transcript: Submit your own questions or specify changes. We’ll conduct a new call with the industry expert, covering both the original and your additional questions. You’ll receive an updated report for a small fee over the standard price.
• Request a Direct Call with the Expert: If you prefer a live conversation, we can facilitate a call between you and the expert. After the call, you’ll get the full recording, a verbatim transcript, and continued platform access to query the content and more.

‍